Cargando…

Prognostic significance of Ki67 in Chinese women diagnosed with ER(+)/HER2(−) breast cancers by the 2015 St. Gallen consensus classification

BACKGROUND: This study evaluated the distribution pattern of the Ki67-labeling index (LI) among patients at a Chinese breast cancer center, and analyzed its prognostic significance in the 2015 St Gallen consensus breast cancer classification, estrogen receptor-positive and human epidermal growth fac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yue, Gu, Ran, Zhao, Jinghua, Yang, Yaping, Liu, Fengtao, Jin, Liang, Chen, Kai, Jia, Haixia, Wang, Hongli, Liu, Qiang, Su, Fengxi, Jia, Weijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5219721/ https://www.ncbi.nlm.nih.gov/pubmed/28061893 http://dx.doi.org/10.1186/s12885-016-3021-7

Ejemplares similares

Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer
por: Bauer, Katrina, et al.
Publicado: (2010)

St.Gallen consensus on safe implementation of transanal total mesorectal excision
por: Adamina, Michel, et al.
Publicado: (2017)

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
por: Gillessen, S., et al.
Publicado: (2015)

Primary therapy of early breast cancer: Egyptian view of 2021 St. Gallen consensus
por: Khaled, Hussein, et al.
Publicado: (2022)

Conversion of ER, PR, HER2 and Ki-67 and Prognosis in breast cancer metastases to the brain
por: Jiaxin, Chen, et al.
Publicado: (2022)

Controversial Opinion of “All pCRs are the Same” in St. Gallen International Consensus Guidelines 2021
por: Cong, Bin-Bin, et al.
Publicado: (2022)

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
por: Coates, A. S., et al.
Publicado: (2015)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Customizing early breast cancer therapies – The 2021 St. Gallen International Breast Cancer Consensus Conference()
por: Gnant, Michael, et al.
Publicado: (2022)

The 14th European Colorectal Congress (#ECCStGallen), 29 November–2 December 2020, St. Gallen, Switzerland
por: Adamina, M., et al.
Publicado: (2021)

Prediction of tumor mutation burden in breast cancer based on the expression of ER, PR, HER-2, and Ki-67
por: Xu, Junnan, et al.
Publicado: (2018)

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
por: Goldhirsch, A., et al.
Publicado: (2009)

The 13th European Colorectal Congress (#ECCStGallen), 1–5 December 2019, St Gallen, Switzerland: Congress Report
por: Adamina, M., et al.
Publicado: (2020)

fHER2, PR, ER, Ki-67 and Cytokeratin 5/6 Expression in Benign Feline Mammary Lesions
por: Soares, Maria, et al.
Publicado: (2022)

Expression changes of ER, PR, HER2, and Ki-67 in primary and metastatic breast cancer and its clinical significance
por: Hu, Xueyang, et al.
Publicado: (2023)

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
por: Untch, Michael, et al.
Publicado: (2021)

Differences in Clinical Outcomes between Luminal A and B Type Breast Cancers according to the St. Gallen Consensus 2013
por: Ahn, Hyo Jung, et al.
Publicado: (2015)

St. Gallen/Vienna 2021: A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer
por: Thomssen, Christoph, et al.
Publicado: (2021)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Stromal Expression of CD10 in Invasive Breast Carcinoma and Its Correlation with ER, PR, HER2-neu, and Ki67
por: Puri, Vandana, et al.
Publicado: (2011)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma
por: Peng, Jian-Heng, et al.
Publicado: (2019)

Abstracts presented at the 14th European Colorectal Congress (#ECCStGallen), 29.11.2020–2.12.2020, St.Gallen, Switzerland
por: Adamina, Michel, et al.
Publicado: (2021)

Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers
por: Luo, Ming, et al.
Publicado: (2019)

Protein co-expression networks identified from HOT lesions of ER+HER2–Ki-67high luminal breast carcinomas
por: Yamada, Kimito, et al.
Publicado: (2021)

Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum
Publicado: (2022)

Application of St Gallen Categories in Predicting Survival for Patients With Breast Cancer in Vietnam
por: Nguyen, Van Chu, et al.
Publicado: (2019)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer—Reduced CK5 Expression in Metastases
por: Joensuu, Kristiina, et al.
Publicado: (2013)

Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women
por: Singhai, Rajeev, et al.
Publicado: (2011)

Invasive Colloid Carcinoma and the role of Ki-67 and HER2 – Two case reports
por: Patel, Sarvanand, et al.
Publicado: (2018)

Spectrum of meningioma with special reference to prognostic utility of ER,PR and Ki67 expression
por: Mukhopadhyay, Madhumita, et al.
Publicado: (2017)

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
por: Goldhirsch, A., et al.
Publicado: (2011)

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
por: Goldhirsch, A., et al.
Publicado: (2013)

Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
por: Burstein, H.J., et al.
Publicado: (2021)

The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients
por: Jia, Weijuan, et al.
Publicado: (2015)

Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015–2018
por: Stevanovic, Lidija, et al.
Publicado: (2019)

The Expression Patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines
por: Subik, Kristina, et al.
Publicado: (2010)

Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer
por: Abubakar, Mustapha, et al.
Publicado: (2019)

A Mathematical Model to Predict Diagnostic Periods for Secondary Distant Metastases in Patients with ER/PR/HER2/Ki-67 Subtypes of Breast Cancer
por: Tyuryumina, Ella Ya., et al.
Publicado: (2020)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_81brt5ui1nicfj5h9it5i3a4v4